Stockreport
G1 Therapeutics to Present at Investor Conferences in March 2018
Last g1 therapeutics earnings: 2/21 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: g1therapeutics.com/pages/investors/investors.htm
PDF
RESEARCH TRIANGLE PARK, N.C., March 01, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the following upcoming investor conferences in March: Cowen and Company 38th Annual Healthcare Conference: Monday, March 12 at 11:20 a.m. ET at the Marriott Copley Place in Boston, MA.Needham & Company 17th Annual Healthcare Conference: Tuesday, March 27 at 8:30 a.m. ET at the Westin Grand Central Hotel in New York, NY. To access the live webcasts of the presentations, please visit the Events & Presentations page within the Investors section of the G1 website. Replays of the webcast will be archived on the same page for 30 days following the event. About G1 TherapeuticsG1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clin
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GTHX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GTHX alerts
GTHX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 THERAPEUTICS news events
Weekly update
A roundup of the hottest topics
GTHX
NEWS
NEWS
- G1 Therapeutics Inc (NASDAQ: GTHX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.[MarketBeat]
- G1 Therapeutics expands executive leadership team [Seeking Alpha][Seeking Alpha]
- G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel[GlobeNewswire]
- G1 Therapeutics Inc (NASDAQ: GTHX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.[MarketBeat]
- G1 Therapeutics Inc (NASDAQ: GTHX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.[MarketBeat]
- More
GTHX
SEC Filings
SEC Filings
- 7/6/18 - Form 4
- 7/6/18 - Form 3
- 7/5/18 - Form 4
- GTHX's page on the SEC website
- More